Overview

Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation

Status:
Completed

Trial end date:
2015-01-22

Target enrollment:

Participant gender:

Summary

Evaluation of efficacy of triple therapy with pegylated interferon, ribavirin, and boceprevir in patients with genotype 1 chronic hepatitis C, who are treatment-naive, have relapsed, or are non-responders with cirrhosis and awaiting liver transplantation, with a MELD score less than or equal to 18

Phase:

Phase 2

Details

Lead Sponsor:

French National Agency for Research on AIDS and Viral Hepatitis

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Interferons
Ribavirin